NCT02160574View on ClinicalTrials.gov

Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Surgical Site Infection
Interventions
DRUG

ChloraPrep

The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.

DRUG

0.1% Sodium Lauryl Sulfate

The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.

DRUG

0.9% Physiological Saline

The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.

OTHER

ZuraPrep without IPA

Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA

Trial Locations (1)

59718

BioScience Laboratories, Bozeman

All Listed Sponsors
lead

Zurex Pharma, Inc.

INDUSTRY

NCT02160574 - Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA | Biotech Hunter | Biotech Hunter